GoAI
Get started
Cardio Diagnostics Holdings, Inc. logo

Cardio Diagnostics Holdings, Inc.

CDIO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.03

−$0.18 · -8.14%

Aug 21, 4:00 PM ET

Pre-market

$2.1461

+$0.1161 · +5.72%

Aug 24, 7:36 AM ET

CDIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

38

Expensive

Momentum

25

Weakening

Sentiment

58

Mixed

Risk resilience

18

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Meeshanthini V. Dogan
Listed since
Jan 14, 2022
Employees
15

Market position

Day range

Current $2.03

52-week range

Current $2.03

Open
$2.19
Previous close
$2.21
Volume
36.87K
0.55× average
Average volume
67.13K
Average daily volume
Market cap
6.01M USD
Beta
2.22
Market reference 1
50-day average
$1.865
+8.85% above average
200-day average
$2.3689
-14.31% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
331.33K USD
P/E (TTM)
-0.7×
P/B (TTM)
0.81×
P/S (TTM)
415.76×
EV / EBITDA
-0.05×
Earnings yield
-136.91%
Free cash flow yield
-124.60%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-555.03%
Operating margin
-44690.68%
Net margin
-44771.83%
Return on equity
-93.19%
Return on assets
-83.67%
Return on invested capital
-84.55%

Financial health

Debt / equity
0.05×
Current ratio
9.79×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends49173%-147119%-343411%-539703%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -68862.15%Operating margin, FY2022: -478784.32%Operating margin, FY2023: -42440.43%Operating margin, FY2024: -23977.86%Operating margin, FY2025: -43737.46%Net margin, FY2021: -68862.15%Net margin, FY2022: -490630.00%Net margin, FY2023: -49087.81%Net margin, FY2024: -24028.24%Net margin, FY2025: -43832.49%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -68862.15%. Operating margin FY2022 -478784.32%. Operating margin FY2023 -42440.43%. Operating margin FY2024 -23977.86%. Operating margin FY2025 -43737.46%. Net margin FY2021 -68862.15%. Net margin FY2022 -490630.00%. Net margin FY2023 -49087.81%. Net margin FY2024 -24028.24%. Net margin FY2025 -43832.49%.

Income trends

Revenue

14.83K USD-57.51%

Operating income

−6.48M USD+22.49%

Net income

−6.5M USD+22.49%
Income trends across reported periods876.72K USD−2.49M USD−5.86M USD−9.23M USDRevenue, FY2021: 901 USDRevenue, FY2022: 950 USDRevenue, FY2023: 17.07K USDRevenue, FY2024: 34.89K USDRevenue, FY2025: 14.83K USDOperating income, FY2021: −620.45K USDOperating income, FY2022: −4.55M USDOperating income, FY2023: −7.24M USDOperating income, FY2024: −8.37M USDOperating income, FY2025: −6.48M USDNet income, FY2021: −620.45K USDNet income, FY2022: −4.66M USDNet income, FY2023: −8.38M USDNet income, FY2024: −8.38M USDNet income, FY2025: −6.5M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 901 USD. Revenue FY2022 950 USD. Revenue FY2023 17.07K USD. Revenue FY2024 34.89K USD. Revenue FY2025 14.83K USD. Operating income FY2021 −620.45K USD. Operating income FY2022 −4.55M USD. Operating income FY2023 −7.24M USD. Operating income FY2024 −8.37M USD. Operating income FY2025 −6.48M USD. Net income FY2021 −620.45K USD. Net income FY2022 −4.66M USD. Net income FY2023 −8.38M USD. Net income FY2024 −8.38M USD. Net income FY2025 −6.5M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue14.83K USD34.89K USD17.07K USD950 USD901 USD
Gross profit14.83K USD34.89K USD17.07K USD950 USD901 USD
Research and development641.21K USD227.97K USD145.18K USD40.45K USD31.47K USD
Selling, general, and administrative5.79M USD8.15M USD7.1M USD4.49M USD573.88K USD
Operating expenses6.5M USD8.4M USD7.26M USD4.55M USD621.35K USD
Interest income712 USD1.06K USD1.07K USD——
Interest expense14.8K USD18.64K USD6.74M USD——
Depreciation and amortization398.13K USD276.35K USD111.62K USD16K USD16K USD
Operating income−6.48M USD−8.37M USD−7.24M USD−4.55M USD−620.45K USD
Net income−6.5M USD−8.38M USD−8.38M USD−4.66M USD−620.45K USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-3.71
FY2025
Latest fiscal-year revenue
14.83K USD
FY2025 · -57.51% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend2.37-14.96-32.3-49.63FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend38.29K24.69K11.1K-2.5KFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution

CDIO news

seekingalpha.com

Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Read source
businesswire.com

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.

Read source
businesswire.com

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.

Read source
businesswire.com

Atlas Healthcare Physicians to Cover Cardio Diagnostics' Precision Cardiovascular Medicine Tests Across Its Network

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that Atlas Healthcare Physicians (AHP) will cover Cardio Diagnostics' tests, Epi+Gen CHD™ and PrecisionCHD™.

Read source
businesswire.com

Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will exhibit at four upcoming national benefits conferences.

Read source

CDIO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CDIO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
31.44K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research CDIO

research.disclaimer